tHEORetically Speaking
Opportunities Abound: How Scientist.com Helps Providers of Market Access Services Grow Their Business
Market access services are essential in today's drug development landscape. Learn how partnering with Scientist.com can help providers grow their business by offering streamlined procurement, targeted visibility, and access to a global biotech audience.
Facilitating Value-Based Agreements with Commercial US Payers using RWE
Explore how real-world evidence (RWE) is shaping value-based care in the US healthcare system. Learn how RWE supports regulatory decisions, insurance coverage, and cost-effective treatment strategies to improve patient outcomes and reduce healthcare spending.
Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group
HealthEconomics.com recently sat down for a conversation with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition for the life science industry. Genesis Research Group empowers life science companies [...]
Enhancing Diversity in Clinical Trials: The Role of Systematic Literature Reviews in FDA’s DEI Initiatives
Systematic literature reviews (SLRs) play a crucial role in shaping inclusive and diverse clinical trials by offering insights into the demographics and health factors of various patient populations. Aligned with the FDA’s DEI initiatives, SLRs help clinical trial sponsors understand the diversity of treatment populations, ensuring trials are representative and addressing potential biases in healthcare research. By drawing on comprehensive data, SLRs support the FDA’s goals for more equitable and generalizable clinical trials.
Market Access “Back to School”: How to Plan and Prioritize Your 2025 Projects
Plan for 2025 in biopharma with insights on adapting to market changes, leveraging digital tools, and engaging key opinion leaders. Ensure guideline inclusion and stay competitive with strategic positioning. Use this checklist to prioritize initiatives for the evolving landscape.
Best practices and opportunities for advancing health equity through research
Health equity is about creating fair opportunities for all individuals to achieve optimal health. Through a structured, three-phase approach—detecting, understanding, and reducing health disparities—researchers and life sciences companies can make meaningful progress toward this goal. By leveraging high-quality data, community partnerships, and multi-level interventions, researchers can address systemic health inequities, ultimately driving better health outcomes for vulnerable populations.
ModEx: Revolutionizing Cancer Drug Pricing and Access Through Open-Source Health Economic Models
Discover how ModEx is transforming cancer drug pricing and accessibility by providing a decentralized platform for open-source health economic models. Learn about the innovative approach to model sharing, including royalty incentives for developers and enhanced validation for users, aimed at ensuring cost-effective healthcare solutions.
Making Real-World Data Research-Ready
With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data. This episode of tHEORetically Speaking features Jeff Brown, PhD and Matvey Palchuk, MD, MS, FAMIA of TriNetX, who discuss the rise of RWD and its role in revolutionizing healthcare research, and how the TriNetX team approaches data quality to ensure research-ready RWD.
Is Your Real-World Data Research-Ready?
Pharmacoepidemiology has evolved with the rise of RWD from diverse sources like EHRs and wearables, enhancing drug safety and effectiveness insights while posing challenges in data quality and purpose-fit, a focus of TriNetX's approach to enabling meaningful healthcare research outcomes.
Unlocking Success: The Crucial Role of Market Access and HEOR in Biotech and Pharma Innovation
Industry experts discuss the importance of integrating market access and health economics early in drug development to enhance commercial success in the biotech and pharmaceutical sectors.
Accelerating Development of Rare Genetic Disease Therapeutics
Healthcare equity is a complex problem. It requires dedicated solutions. By working with the right data partner, researchers can gather real-world data aimed at better understanding patient healthcare journeys. HEOR studies can yield new insights into disparities, presenting opportunities to create a more equitable healthcare system in which patient economic factors and geography don’t limit access to care.
The Only Constant is Change
ADVI Health, known for its data-informed commercialization, market access, and policy work, has acquired Partnership for Health Analytic Research (PHAR), known for analytic expertise and scientific rigor.
Advancing Health Equity by Leveraging Social Determinants of Health Data
Healthcare equity is a complex problem. It requires dedicated solutions. By working with the right data partner, researchers can gather real-world data aimed at better understanding patient healthcare journeys. HEOR studies can yield new insights into disparities, presenting opportunities to create a more equitable healthcare system in which patient economic factors and geography don’t limit access to care.
The race to develop combination vaccines – and the importance of indirect effects
By: Richard Pitman, PhD & Rosanna Barnard, PhD from ICON A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-191. The benefits of new combination vaccines are numerous – fewer injections [...]
Computable Phenotypes: A Rose by Any Other Name
By: Michael S. Broder, MD, MSHS, President - PHAR “What’s in a name? That which we call a rose/ By any other name would smell as sweet.” --William Shakespeare, Romeo and Juliet If you attended the ISPOR International conference in May, you couldn’t have missed that the most common [...]